Other Information
−Removed: None of our directors or executive officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement during the quarter ended September 30, 2025, as such terms are defined under Item 408 (a) of Regulation S-K.
−Removed: Additionally, we did not adopt or terminate a Rule 10b5–1 trading arrangement during the quarter ended September 30, 2025.
+Added: None of our directors or executive officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement during the quarter ended March 31, 2026, as such terms are defined under Item 408 (a) of Regulation S-K.
+Added: Additionally, we did not adopt or terminate a Rule 10b5 - 1 trading arrangement during the quarter ended March 31, 2026.
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
15 unchanged sentences
NRX PHARMACEUTICALS, INC.
−Removed: November 14, 2025
/s/ Jonathan Javitt
−Removed: Chairman and Interim Chief Executive Officer
+Added: Chairman and Chief Executive Officer
(Principal Executive Officer)
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
+Added: NRX PHARMACEUTICALS, INC.
+Added: /s/ Michael Abrams
+Added: Chief Financial Officer
+Added: (Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.